Analyzing iCo Therapeutics (OTCMKTS:ICOTF) & Clearside Biomedical (CLSD)

March 16, 2019
121 Views


iCo Therapeutics (OTCMKTS:ICOTF) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Profitability

This table compares iCo Therapeutics and Clearside Biomedical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
iCo Therapeutics N/A -201.81% -133.62%
Clearside Biomedical N/A -126.32% -94.88%

Earnings and Valuation

This table compares iCo Therapeutics and Clearside Biomedical’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
iCo Therapeutics N/A N/A -$950,000.00 N/A N/A
Clearside Biomedical $30,000.00 1,515.80 -$58.97 million ($2.69) -0.53

iCo Therapeutics has higher earnings, but lower revenue than Clearside Biomedical.

Volatility and Risk

iCo Therapeutics has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of -1.13, indicating that its stock price is 213% less volatile than the S&P 500.

Institutional and Insider Ownership

39.9% of Clearside Biomedical shares are held by institutional investors. 15.4% of Clearside Biomedical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for iCo Therapeutics and Clearside Biomedical, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iCo Therapeutics 0 0 0 0 N/A
Clearside Biomedical 1 2 5 0 2.50

Clearside Biomedical has a consensus target price of $11.83, suggesting a potential upside of 733.33%. Given Clearside Biomedical’s higher probable upside, analysts clearly believe Clearside Biomedical is more favorable than iCo Therapeutics.

Summary

Clearside Biomedical beats iCo Therapeutics on 7 of the 9 factors compared between the two stocks.

About iCo Therapeutics

iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections. The company was founded in 2005 and is headquartered in Vancouver, Canada.

About Clearside Biomedical

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema. The company also engages in the development of therapies in various areas, such as gene therapy for inherited retinal disorders, neovascular age-related macular degeneration, and other ocular diseases. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.

Receive News & Ratings for iCo Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for iCo Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.



Source link

You may be interested

Bitcoin, Ethereum, Ripple, Bitcoin Cash, Litecoin, EOS, Binance Coin, Stellar, Cardano, TRON: Price Analysis April 29 – Cointelegraph
Litecoin News
412 views
Litecoin News
412 views

Bitcoin, Ethereum, Ripple, Bitcoin Cash, Litecoin, EOS, Binance Coin, Stellar, Cardano, TRON: Price Analysis April 29 – Cointelegraph

Editor - April 29, 2019

[ad_1] Bitcoin, Ethereum, Ripple, Bitcoin Cash, Litecoin, EOS, Binance Coin, Stellar, Cardano, TRON: Price Analysis April 29  CointelegraphPrice Analysis. The views…

(BTC) Bitcoin Price Prediction 2019 / 2020 / 5 years (Updated 04/29/2019): BTC/USD Rises From Support – BeInCrypto
Litecoin News
397 views
Litecoin News
397 views

(BTC) Bitcoin Price Prediction 2019 / 2020 / 5 years (Updated 04/29/2019): BTC/USD Rises From Support – BeInCrypto

Editor - April 29, 2019

[ad_1] (BTC) Bitcoin Price Prediction 2019 / 2020 / 5 years (Updated 04/29/2019): BTC/USD Rises From Support  BeInCryptoHow will Bitcoin (BTC)…

Litecoin (LTC) price analysis: LTC/USD hovers below $70.00, more sell-off is possible – FXStreet
Litecoin News
334 views
Litecoin News
334 views

Litecoin (LTC) price analysis: LTC/USD hovers below $70.00, more sell-off is possible – FXStreet

Editor - April 29, 2019

[ad_1] Litecoin (LTC) price analysis: LTC/USD hovers below $70.00, more sell-off is possible  FXStreetLitecoin (LTC) peaked at $99.47 on April 3…

Leave a Comment

Your email address will not be published.